Comorbidities in a Cohort of 66 Patients With Psoriatic Arthritis Mutilans-Results From the Nordic PAM Study

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review


  • Josephine Mistegård, Aarhus University
  • ,
  • Bjorn Gudbjornsson, Univ Iceland, Landspitali National University Hospital, University of Iceland, Natl Univ Hosp Iceland
  • ,
  • Ulla Lindqvist, Uppsala University
  • ,
  • Leena Laasonen, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.
  • ,
  • Leif Ejstrup, Odense Universitetshospital
  • ,
  • Mona Ståhle, Karolinska Institutet
  • ,
  • Lars Iversen

Objective: Psoriatic arthritis mutilans (PAM) is the most severe phenotype of psoriatic arthritis due to excessive bone erosion causing joint destruction and decreased functional capacity. The aim of this study was to investigate the prevalence of comorbidities among patients with PAM and the association between comorbidities and joint involvement. Methods: A total of 66 patients aged ≥18 years from the Nordic countries with past or present psoriasis along with at least one mutilated joint were included in the present study. Results: The median number of comorbid conditions per patient was 1 [interquartile range (IQR) 0-2] and 16.7% reported three or more comorbidities. The most frequent comorbidity was hypertension (36.4%). The median number of mutilated joints per patient was 3 (IQR 1-8.3; range 1-38). Conclusion: Two thirds of the patients with PAM reported comorbid conditions and the most frequent was hypertension which affected more than a third of the patients. However, this study was unable to detect any association between comorbidities and the severity of PAM.

Original languageEnglish
Article number629741
JournalFrontiers in medicine
Number of pages8
Publication statusPublished - 2021

See relations at Aarhus University Citationformats

ID: 213753457